Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Income towards Parent Company (2016 - 2022)

Historic Income towards Parent Company for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to $521000.0.

  • Aptevo Therapeutics' Income towards Parent Company rose 6030.77% to $521000.0 in Q4 2022 from the same period last year, while for Sep 2023 it was $521000.0, marking a year-over-year decrease of 3623.01%. This contributed to the annual value of -$18.6 million for FY2023, which is 194106.61% down from last year.
  • According to the latest figures from Q4 2022, Aptevo Therapeutics' Income towards Parent Company is $521000.0, which was up 6030.77% from $165000.0 recorded in Q3 2022.
  • In the past 5 years, Aptevo Therapeutics' Income towards Parent Company ranged from a high of $5.2 million in Q3 2019 and a low of -$12.9 million during Q2 2019
  • Moreover, its 5-year median value for Income towards Parent Company was $140500.0 (2021), whereas its average is -$1.2 million.
  • Within the past 5 years, the most significant YoY rise in Aptevo Therapeutics' Income towards Parent Company was 1313076.92% (2019), while the steepest drop was 11733636.36% (2019).
  • Aptevo Therapeutics' Income towards Parent Company (Quarter) stood at $39000.0 in 2018, then soared by 4666.67% to $1.9 million in 2019, then crashed by 93.65% to $118000.0 in 2020, then skyrocketed by 175.42% to $325000.0 in 2021, then skyrocketed by 60.31% to $521000.0 in 2022.
  • Its Income towards Parent Company stands at $521000.0 for Q4 2022, versus $165000.0 for Q3 2022 and $149000.0 for Q2 2022.